A comparable number of adverse events and serious adverse events were seen across treatment groups during the first three months and did not appear to increase thereafter
Diamyd Medical AB, of Stockholm, Sweden, said Phase I results published in the Annals of Neurology showed that drug candidate NP2 Enkephalin in intractable cancer pain was well tolerated through four months, with no observed treatment-related serious adverse events
Silence Therapeutics plc, of London, and partner Quark Pharmaceuticals Inc., of Fremont, Calif., reported interim 12-month data from the Phase II DEGAS study in diabetic macular edema showing that PF-04523655 (RTP801I-14) produced no drug-related serious adverse events and demonstrated the best results at the 3-mg dose level, with mean improvement from baseline on a visual acuity test of 5.8 letters in the treatment group vs. 2.4 letters in patients treated with laser photocoagulation control
No serious adverse events were reported and, in those vaccinated in the 18 to 49 age group at the 20 mcg dosage level, 82 percent developed an immune response against the H5N1 virus after the second immunization, while 65 percent of subjects had a fourfold increase in HI titers from baseline and 65 percent had seroprotective antibody titers
No serious adverse reactions were experienced, and the company is planning to move into Phase II...A preliminary analysis of all data available at the end of 12 weeks of dosing revealed no serious adverse events and no discontinuations due to adverse events
The study tested single doses of the drug in two cohorts of healthy volunteers, with results showing that it was well tolerated, had good bioavailability and did not cause any serious adverse events
Additional data showed that onset of efficacy was seen at three days to five days of treatment, and the product was shown to be safe and well tolerated with no serious adverse events and no reported site irritation...Immunovaccine Inc., of Halifax, Nova Scotia, said results from a Phase I trial showed that DPX-0907, a DepoVax-based therapeutic cancer vaccine for advanced breast, ovarian or prostate cancers, has resulted in no dose-limiting toxicities or serious adverse events
Anthera said there have been no reports of patient-related side effects or problems with drug administration that could be attributed to the problem to date, and no serious adverse events have been reported to the company in the PEARL-SC trial
Icagen Inc., of Research Triangle Park, N.C., said it suspended further enrollment in its photosensitivity study of ICA-105665 due to a serious adverse event...ViroPharma Inc., of Exton, Pa., presented Phase I data showing that VP20621 was well tolerated with no serious adverse events and no discontinuations due to adverse events
An independent safety review board reviewed all of the safety data from the clinical trial and preliminary results demonstrated that Bendavia appears to be safe and well tolerated at the doses evaluated, with no serious adverse events reported
Results also showed that the drug demonstrated safety and tolerability, with no treatment-related gastrointestinal, cardiac, liver or other serious adverse events
Preliminary data showed that the drug was well tolerated at all dose levels, with no drug-related serious adverse events or dose-related trends in frequency or type of adverse events
A comparable number of adverse events and serious adverse events were seen across treatment groups during the first three months and did not appear to increase thereafter